152 related articles for article (PubMed ID: 38365960)
1. Booster vaccination with SARS-CoV-2 mRNA vaccines and myocarditis in adolescents and young adults: a Nordic cohort study.
Hviid A; Nieminen TA; Pihlström N; Gunnes N; Dahl J; Karlstad Ø; Gulseth HL; Sundström A; Husby A; Hansen JV; Ljung R; Hovi P
Eur Heart J; 2024 Apr; 45(15):1327-1335. PubMed ID: 38365960
[TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents.
Karlstad Ø; Hovi P; Husby A; Härkänen T; Selmer RM; Pihlström N; Hansen JV; Nohynek H; Gunnes N; Sundström A; Wohlfahrt J; Nieminen TA; Grünewald M; Gulseth HL; Hviid A; Ljung R
JAMA Cardiol; 2022 Jun; 7(6):600-612. PubMed ID: 35442390
[TBL] [Abstract][Full Text] [Related]
3. SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study.
Husby A; Hansen JV; Fosbøl E; Thiesson EM; Madsen M; Thomsen RW; Sørensen HT; Andersen M; Wohlfahrt J; Gislason G; Torp-Pedersen C; Køber L; Hviid A
BMJ; 2021 Dec; 375():e068665. PubMed ID: 34916207
[TBL] [Abstract][Full Text] [Related]
4. Risk of myocarditis and pericarditis after a COVID-19 mRNA vaccine booster and after COVID-19 in those with and without prior SARS-CoV-2 infection: A self-controlled case series analysis in England.
Stowe J; Miller E; Andrews N; Whitaker HJ
PLoS Med; 2023 Jun; 20(6):e1004245. PubMed ID: 37285378
[TBL] [Abstract][Full Text] [Related]
5. Postmarketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12 to 39 years in Italy: A multi-database, self-controlled case series study.
Massari M; Spila Alegiani S; Morciano C; Spuri M; Marchione P; Felicetti P; Belleudi V; Poggi FR; Lazzeretti M; Ercolanoni M; Clagnan E; Bovo E; Trifirò G; Moretti U; Monaco G; Leoni O; Da Cas R; Petronzelli F; Tartaglia L; Mores N; Zanoni G; Rossi P; Samez S; Zappetti C; Marra AR; Menniti Ippolito F;
PLoS Med; 2022 Jul; 19(7):e1004056. PubMed ID: 35900992
[TBL] [Abstract][Full Text] [Related]
6. Risk of Myocarditis After Sequential Doses of COVID-19 Vaccine and SARS-CoV-2 Infection by Age and Sex.
Patone M; Mei XW; Handunnetthi L; Dixon S; Zaccardi F; Shankar-Hari M; Watkinson P; Khunti K; Harnden A; Coupland CAC; Channon KM; Mills NL; Sheikh A; Hippisley-Cox J
Circulation; 2022 Sep; 146(10):743-754. PubMed ID: 35993236
[TBL] [Abstract][Full Text] [Related]
7. Epidemiology of Myocarditis and Pericarditis Following mRNA Vaccination by Vaccine Product, Schedule, and Interdose Interval Among Adolescents and Adults in Ontario, Canada.
Buchan SA; Seo CY; Johnson C; Alley S; Kwong JC; Nasreen S; Calzavara A; Lu D; Harris TM; Yu K; Wilson SE
JAMA Netw Open; 2022 Jun; 5(6):e2218505. PubMed ID: 35749115
[TBL] [Abstract][Full Text] [Related]
8. Safety of heterologous primary and booster schedules with ChAdOx1-S and BNT162b2 or mRNA-1273 vaccines: nationwide cohort study.
Andersson NW; Thiesson EM; Laursen MV; Mogensen SH; Kjær J; Hviid A
BMJ; 2022 Jul; 378():e070483. PubMed ID: 35831006
[TBL] [Abstract][Full Text] [Related]
9. Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases.
Wong HL; Hu M; Zhou CK; Lloyd PC; Amend KL; Beachler DC; Secora A; McMahill-Walraven CN; Lu Y; Wu Y; Ogilvie RP; Reich C; Djibo DA; Wan Z; Seeger JD; Akhtar S; Jiao Y; Chillarige Y; Do R; Hornberger J; Obidi J; Forshee R; Shoaibi A; Anderson SA
Lancet; 2022 Jun; 399(10342):2191-2199. PubMed ID: 35691322
[TBL] [Abstract][Full Text] [Related]
10. Myocarditis and/or pericarditis risk after mRNA COVID-19 vaccination: A Canadian head to head comparison of BNT162b2 and mRNA-1273 vaccines.
Abraham N; Spruin S; Rossi T; Fireman B; Zafack J; Blaser C; Shaw A; Hutchings K; Ogunnaike-Cooke S
Vaccine; 2022 Jul; 40(32):4663-4671. PubMed ID: 35750537
[TBL] [Abstract][Full Text] [Related]
11. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection.
Patone M; Mei XW; Handunnetthi L; Dixon S; Zaccardi F; Shankar-Hari M; Watkinson P; Khunti K; Harnden A; Coupland CAC; Channon KM; Mills NL; Sheikh A; Hippisley-Cox J
Nat Med; 2022 Feb; 28(2):410-422. PubMed ID: 34907393
[TBL] [Abstract][Full Text] [Related]
12. A population-based assessment of myocarditis after messenger RNA COVID-19 booster vaccination among adult recipients.
Naveed Z; Li J; Naus M; Velásquez García HA; Wilton J; Janjua NZ;
Int J Infect Dis; 2023 Jun; 131():75-78. PubMed ID: 36967038
[TBL] [Abstract][Full Text] [Related]
13. Observed versus expected rates of myocarditis after SARS-CoV-2 vaccination: a population-based cohort study.
Naveed Z; Li J; Spencer M; Wilton J; Naus M; García HAV; Otterstatter M; Janjua NZ
CMAJ; 2022 Nov; 194(45):E1529-E1536. PubMed ID: 36410749
[TBL] [Abstract][Full Text] [Related]
14. Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study.
Wong CKH; Lau KTK; Xiong X; Au ICH; Lai FTT; Wan EYF; Chui CSL; Li X; Chan EWY; Gao L; Cheng FWT; Tang SCW; Wong ICK
PLoS Med; 2022 Jun; 19(6):e1004018. PubMed ID: 35727759
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial.
Oda Y; Kumagai Y; Kanai M; Iwama Y; Okura I; Minamida T; Yagi Y; Kurosawa T; Greener B; Zhang Y; Walson JL
Lancet Infect Dis; 2024 Apr; 24(4):351-360. PubMed ID: 38141632
[TBL] [Abstract][Full Text] [Related]
16. Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021.
Oster ME; Shay DK; Su JR; Gee J; Creech CB; Broder KR; Edwards K; Soslow JH; Dendy JM; Schlaudecker E; Lang SM; Barnett ED; Ruberg FL; Smith MJ; Campbell MJ; Lopes RD; Sperling LS; Baumblatt JA; Thompson DL; Marquez PL; Strid P; Woo J; Pugsley R; Reagan-Steiner S; DeStefano F; Shimabukuro TT
JAMA; 2022 Jan; 327(4):331-340. PubMed ID: 35076665
[TBL] [Abstract][Full Text] [Related]
17. Comparative effectiveness of heterologous third dose vaccine schedules against severe covid-19 during omicron predominance in Nordic countries: population based cohort analyses.
Andersson NW; Thiesson EM; Baum U; Pihlström N; Starrfelt J; Faksová K; Poukka E; Lund LC; Hansen CH; Aakjær M; Kjær J; Cohet C; Goossens M; Andersen M; Hallas J; Meijerink H; Ljung R; Hviid A
BMJ; 2023 Jul; 382():e074325. PubMed ID: 37487623
[TBL] [Abstract][Full Text] [Related]
18. Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review.
Pillay J; Gaudet L; Wingert A; Bialy L; Mackie AS; Paterson DI; Hartling L
BMJ; 2022 Jul; 378():e069445. PubMed ID: 35830976
[TBL] [Abstract][Full Text] [Related]
19. Risk of myocarditis and pericarditis following BNT162b2 and mRNA-1273 COVID-19 vaccination.
Goddard K; Lewis N; Fireman B; Weintraub E; Shimabukuro T; Zerbo O; Boyce TG; Oster ME; Hanson KE; Donahue JG; Ross P; Naleway A; Nelson JC; Lewin B; Glanz JM; Williams JTB; Kharbanda EO; Katherine Yih W; Klein NP
Vaccine; 2022 Aug; 40(35):5153-5159. PubMed ID: 35902278
[TBL] [Abstract][Full Text] [Related]
20. COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals.
Faksova K; Walsh D; Jiang Y; Griffin J; Phillips A; Gentile A; Kwong JC; Macartney K; Naus M; Grange Z; Escolano S; Sepulveda G; Shetty A; Pillsbury A; Sullivan C; Naveed Z; Janjua NZ; Giglio N; Perälä J; Nasreen S; Gidding H; Hovi P; Vo T; Cui F; Deng L; Cullen L; Artama M; Lu H; Clothier HJ; Batty K; Paynter J; Petousis-Harris H; Buttery J; Black S; Hviid A
Vaccine; 2024 Apr; 42(9):2200-2211. PubMed ID: 38350768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]